Chrysea and KaloCyte form exclusive alliance to advance biosynthetic blood solutions

Chrysea and KaloCyte have entered into an exclusive strategic alliance intended to accelerate development and deployment of a biosynthetic red blood cell substitute for medical emergencies. According to the companies, Chrysea will apply its synthetic biology platform in conjunction with KaloCyte’s artificial red blood cell technology to address urgent blood needs when donor supply is […] The post Chrysea and KaloCyte form exclusive alliance to advance biosynthetic blood solutions appeared first on Longevity.Technology.